ArticleCancer immunology, immunotherapy : CII2023

Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab.

Anna Siemiątkowska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.